Going into to 2023, Pharmaxis will have two Phase II study results to report. One is with PXS-6302 in the treatment of scars, and the second is with PXS-5505 for the treatment of myelofibrosis.

Pharmaxis (PXS: $0.066) has two drug candidates in clinical development, both based on its lysyl oxidase inhibition platform that seeks to reduce or stop collagen crosslinking that is crucial to the fibrosis process. The drug candidates are PXS-5505, being trialled in a Phase II study in myelofibrosis, and a second investigator-led study in liver cancer due to commence this year; as well as PXS-6302, which is being investigated as a treatment for existing and new scars. The trial in existing scars has reached the 75% recruitment mark.

Pharmaxis (PXS: $0.081) has released some data on the first eight patients treated with its drug candidate, PXS-6302, to remove existing scars. The first eight patients were all treated with PXS-6302 whilst the next 42 being recruited are blinded between placebo or active arms.

Pharmaxis (PXS: $0.084) is using its lysyl oxidase platform to develop a topical application for the removal of scars. Results are due around year's end and may be a driver for this stock over coming months.

Pharmaxis (PXS: $0.084) is using its lysyl oxidase platform to develop a topical application for the removal of scars. Results are due around year's end and may be a driver for this stock over coming months.

Pharmaxis CEO Gary Phillips said that the company has the first-in-class and best-in-class compounds in this field. According to Phillips at an R&D day earlier this year, the reason why Pharmaxis has extended its R&D programs into scarring is because it's where the science has led the company to.

Since Boehringer Ingelheim returned the Pharmaxis (PXS: $0.076) drug candidate PXS-4728 in 2020, Pharmaxis has been seeking to find a new indication to trial for the compound, given the level of development work that had been carried out on the compound by Boehringer.

Pharmaxis (PXS: $0.077) has executed a deal for the license and sale of its Orbital drug inhalation device with Aptar Pharma for US$5 million.

On a recent investor call, Pharmaxis (PXS: $0.097) CEO Gary Phillips said that the company's Phase I/IIa trial in patients with myelofibrosis is on target to complete recruitment by mid-year with results still due at the end of the year.